Condensed low-dose total skin electron beam therapy for mycosis fungoides: an institutional retrospective review and subgroup analysis of patients with large cell transformation
Archives of Dermatological Research · 2025
DOI: 10.1007/s00403-025-04030-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Archives of Dermatological Research, 2025. Verfasst von Louis Cappelli und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA. Louis.Cappelli@jefferson.edu. Hauptthemen laut MEDLINE: Mycosis Fungoides, Electrons, Skin Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Low-dose total skin electron beam therapy (TSEBT) is an effective treatment option for mycosis fungoides (MF) with proven palliative effects and reduced toxicity. Presented is an institutional analysis of survival/response rate and quality of life for MF patients with subgroup analysis of those possessing pathologic large cell transformation (LCT). This is a single institutional retrospective review of patients with mycosis fungicides treated from 2014 to 2023 with low-dose TSEBT. All patients received 12 Gy in 6 fractions every other day with the modified Stanford technique, with boosts to shadowed sites between treatments, completed in 2 weeks. Outcomes evaluated included clinical response, duration of and time to response, patient-reported quality of life, and physician-scored disease burden. Forty-six patients were included in the study, 28 male and 18 female, with a median age 66.5 (range 32.7–90.6). Stage IB was most common at the time of TSEBT (41.3%). Median follow up was 44.5 months. The overall response rate was 91.3% (52.2% partial response, 19.6% complete and near complete response). The median duration of response was 8.2 months (range, 6.1–28.7), and the median time to best response was 3.5 months (range, 2.7–5.6). Quality of life (QOL) and disease burden continued to show significant benefit after TSEBT ( p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA. Louis.Cappelli@jefferson.edu.
- Department of Radiation Oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, 111 St 11th Street, Philadelphia, Pennsylvania, 19107, USA. Louis.Cappelli@jefferson.edu.
- Department of Dermatology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
- Department of Radiation Oncology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
- Sidney Kimmel Medical College, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
- Department of Pharmacology, Physiology and Cancer Biology, Thomas Jefferson University Hospital, Philadelphia, PA, USA.
Zitieren
APA
Cappelli, L., Cappelli, M., Haldar, N., Paul, T., Mandel, J., Zhan, T., Nikbakht, N., & Shi, W. (2025). Condensed low-dose total skin electron beam therapy for mycosis fungoides: an institutional retrospective review and subgroup analysis of patients with large cell transformation. Archives of Dermatological Research. https://doi.org/10.1007/s00403-025-04030-3
Vancouver
Cappelli L, Cappelli M, Haldar N, Paul T, Mandel J, Zhan T, et al. Condensed low-dose total skin electron beam therapy for mycosis fungoides: an institutional retrospective review and subgroup analysis of patients with large cell transformation. Archives of Dermatological Research. 2025. doi:10.1007/s00403-025-04030-3
BibTeX
@article{Cappelli2025,
author = {Cappelli, Louis and Cappelli, Megan and Haldar, Nilanjan and Paul, Tiara and Mandel, Jenna and Zhan, Tingting and Nikbakht, Neda and Shi, Wenyin},
title = {Condensed low-dose total skin electron beam therapy for mycosis fungoides: an institutional retrospective review and subgroup analysis of patients with large cell transformation},
journal = {Archives of Dermatological Research},
year = {2025},
doi = {10.1007/s00403-025-04030-3}
}
EUVIMED